Satellos Q2 FY26 net loss widens to USD 11.7 million; R&D expense more than doubles to USD 9.6 million

Reuters2026/08/13 21:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Satellos posted a Q2 net loss of USD 11.7 million, widening from USD 5.6 million a year earlier.
RD expense more than doubled to USD 9.6 million, driven by higher TRAILHEAD and BASECAMP study costs and CMC spending.
GA costs climbed 31.1% to USD 2.5 million on higher headcount, Nasdaq-related public reporting fees, and other professional services.
Cash, cash equivalents, short-term investments rose to USD 61.8 million at June 30, providing expected runway through 2027.
SAT-3247 won FDA Fast Track designation; BASECAMP pediatric Phase 2 data due in Q4 2026, TRAILHEAD update also planned in Q4.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satellos Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131702PRIMZONEFULLFEED9809906) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Satellos Q2 FY26 net loss widens to USD 11.7 million; R&D expense more than doubles to USD 9.6 million

You may also like

Crypto prices